Mountainfield Venture Partners, a
biopharmaceutical company creation firm, partners with Keymed
Biosciences to form Timberlyne Therapeutics, accessing global
development and commercial rights outside of greater China for CM313
Financing co-led by Abingworth, Bain Capital
Life Sciences, and Venrock Healthcare Capital Partners
SAN
DIEGO, Jan. 9, 2025 /PRNewswire/ -- Timberlyne
Therapeutics, a clinical-stage biopharmaceutical company focused on
the development of novel therapies for autoimmune disorders, today
announced the close of a $180 million
Series A financing to advance CM313, a potentially best-in-class
monoclonal antibody targeting CD38, for diseases of high unmet
medical needs. The financing was led by investors Abingworth, Bain
Capital Life Sciences, and Venrock Healthcare Capital Partners,
with participation from Boyu Capital, Lilly Asia Ventures,
Braidwell LP, and 3H Health Investment. Timberlyne
Therapeutics was formed by Mountainfield Venture Partners, a
biopharma company creation firm, in partnership with Keymed
Biosciences.
Timberlyne has obtained exclusive development and
commercialization rights to CM313 worldwide outside of greater
China from Keymed Biosciences, a
leading drug discovery and development company. Under the terms of
the licensing agreement, Keymed will receive an undisclosed upfront
payment, as well as future cash milestones, royalties on any
potential future net sales, and equity ownership in Timberlyne.
Keymed retains development and commercialization rights in greater
China.
CM313 is an IgG1 monoclonal antibody with
enhanced complement-dependent cytotoxicity and has been clinically
studied across numerous disease states, including immune
thrombocytopenic purpura, systemic lupus erythematosus, and
relapsed/refractory multiple myeloma. Across these trials, CM313
has demonstrated potentially best-in-class characteristics. The
therapeutic potential of CM313 was demonstrated in a clinical study
recently published in the New England Journal of Medicine, where
the drug candidate achieved a 95% response rate in patients with
treatment-refractory Immune Thrombocytopenia.
About Timberlyne Therapeutics
Timberlyne Therapeutics is a clinical-stage biopharmaceutical
company focused on the development and commercialization of
transformational therapies for high unmet medical needs.
Timberlyne's lead program is CM313, an IgG1 monoclonal antibody
with enhanced complement-dependent cytotoxicity that targets CD38.
By targeting CD38, which is highly expressed on plasma cells, NK
cells, and other immune cells, CM313 modulates multiple immune cell
types leading to both rapid and durable responses across a range of
autoimmune diseases and cancers.
About Keymed Biosciences
Keymed Biosciences Inc. (HKEX: 02162) focuses on
the urgent unmet clinical needs, and is committed to providing
high-quality, affordable, innovative therapies for patients in
China and overseas. Keymed was
founded by medical and scientific experts from world-renowned
universities who have strong experience in the transformation of
scientific and technological achievements to commercialization at
home and abroad. The core leadership team includes the inventors of
the first PD-1 antibody drugs that were pioneered and approved in
the United States and China. The Company was listed on the main
board of Hong Kong Stock Exchange on July 8,
2021.
To accelerate the efficiency of our research and
discovery, we have established a fully-integrated platform
encompassing all of the key functions in the biologic drug
development. These include target validation, lead molecule
discovery and optimization, preclinical evaluation, process
development, translational research, clinical development and
manufacturing. This integrated platform has enabled us to rapidly
and cost-effectively identify, build, expand and advance our
diversified pipeline of innovative and differentiated
antibody-based therapies, including monoclonal antibodies, antibody
drug conjugates (ADCs) and bispecific antibodies.
About Mountainfield Venture Partners
Mountainfield Venture Partners is a biopharmaceutical company
creation firm that builds new companies around development-stage
drug candidates with the potential to transform patient care. We
form our companies around in-licensed drug candidates, world-class
leadership teams, and syndicated capital raises from top-tier life
science institutional investors. We also develop the strategy and
establish the operations for our companies based on our long track
record in biopharmaceutical leadership and operational roles
spanning from small start-up biotechnology companies to
multi-national pharmaceutical companies.
Contacts
For Timberlyne Therapeutics:
info@timberlyne-tx.com
For Mountainfield Venture Partners:
contact@mountainfieldvp.com
For Media:
amy@juniper-point.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/timberlyne-therapeutics-launches-with-a-180-million-series-a-financing-to-advance-cm313-a-potentially-best-in-class-anti-cd38-monoclonal-antibody-for-diseases-of-high-unmet-medical-needs-302347636.html
SOURCE Timberlyne Therapeutics
